NeuroMab™ Anti-CD32b Antibody, Clone NR130P
Functional antibody against Human CD32b
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- ELISA; WB; ADCC; Cyt; Block; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryImmunogen
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Shipping
Storage
Research Use Only
Figure 1 shows the binding of anti-CD32b antibodies to (Figure 1A) CD32bECDHis and (Figure 1B) CD32aECDHis measured by ELISA.
Figure 10 shows the binding of anti-CD32b antibodies to human peripheral blood leukocytes.
Figure 11 shows the binding of anti-CD32b antibody to CD32bECDHis in Western blot. Under reducing (lanes 1-6) and non-reducing conditions (9-12).
Figure 2 shows the binding of anti-CD32b antibodies to stably transfected IIA1.6 cells expressing full-length CD32b measured by flow cytometry.
Figure 3 shows the ability of anti-CD32b antibody to induce Daudi cell lysis by ADCC compared to HuMab-KLH
Figure 4 shows CD32b TR-FRET based binding competition data. Maximum TR-FRET fluorescence was determined in samples without unlabeled mAb (which did not compete with labeled mAb). Background fluorescence was measured in samples without CD32bECDHis and CD32aECDHis. The inhibition of a-KLH-AlexaFluor 647 binding to CD32bECDHis and CD32aECDHis was represented by IC50 values (Table 6). The data for antibody 026 illustrate antibodies 020, 022, 024, 028, 053 and 063.
Figure 5 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 0 (Figure 5A) or day 6 (Figure 5B) after tumor challenge; shown are mean counts per minute (cpm) values ± SEM for each treatment group.
Figure 6 shows the in vivo anti-tumor efficacy of anti-CD32b antibodies in a xenograft tumor model in SCID mice. Antibody was administered on day 6 (Figure 6A and 6B) or 14 days after tumor challenge (Figure 6C); data shown are mean tumor burden ± SEM for each group.
Figure 7 shows the ability of anti-CD32b antibodies to induce Daudi cell lysis by ADCC compared to HuMab-KLH. Data shown are mean ± SEM of triplicates.
Figure 8 shows the binding of anti-CD32b antibodies to membrane-bound CD32b1 expressed on IIA1.6 cells. Data shown are mean MFI ± stdev of three independent experiments.
Figure 9 shows the binding of anti-CD32b antibodies to mantle cell lymphoma cells.
Publications (0)
